NSAIDs, Local Treatment and Conventional DMARDs
Understand the roles and limits of NSAIDs, injections, glucocorticoids and conventional disease-modifying medicines.
All chapters in this collection
Understanding the diagnosis
- 1. Peripheral SpA, Undifferentiated SpA and a Working Diagnosis
- 2. Joints, Entheses and Dactylitis: Understanding the Peripheral Pattern
- 3. How the Diagnosis Is Built
- 4. New Symptoms: What Changes the Picture and When Not to Wait
Tests and imaging
- 5. Blood Tests and HLA-B27: What They Can and Cannot Tell You
- 6. Ultrasound, MRI, X-ray and Joint Aspiration: Choosing the Right Test
Treatment decisions
- 7. What Are We Actually Trying to Improve?
- 8. NSAIDs, Local Treatment and Conventional DMARDs
- 9. When Targeted Therapy Enters the Discussion
Daily life and follow-up
- 10. Movement, Feet, Hands, Work and Everyday Load
- 11. How Do We Know Treatment Is Working?
- 12. Pregnancy, Infection, Surgery and Other Medical Conditions
When the picture changes
- 13. Why the Diagnosis May Change
- 14. When Pain, Examination, Blood Tests and Imaging Disagree
- 15. Remission, Treatment Reduction and Long-Term Outlook
Research and future care
Treatment is selected for the tissue and disease pattern being addressed. A medicine that helps joint synovitis may not be effective for spinal inflammation or for a mechanically overloaded tendon. Understanding each treatment’s job makes follow-up more useful.
NSAIDs: symptom relief with an individual risk assessment
Nonsteroidal anti-inflammatory drugs, or NSAIDs, include medicines such as ibuprofen, naproxen and celecoxib. They may reduce inflammatory pain and stiffness. A good response can improve function, but it does not independently confirm the diagnosis or demonstrate that every longer-term disease consequence has been prevented.
Risks include stomach irritation or bleeding, kidney problems, fluid retention and cardiovascular concerns. The choice depends on other illnesses and medicines. Over-the-counter availability does not remove these risks. Check before combining products because different brand names may contain the same drug class.
Dehydration from vomiting or diarrhea can change kidney risk. Ask for a plan for illness days and for situations when your usual medicine may no longer be appropriate. Avoid copying another patient’s schedule.
Local treatment: a focused problem may need a focused response
An injection into an inflamed joint can sometimes reduce a troublesome local problem. It does not treat every manifestation elsewhere. Before injecting a newly hot swollen joint, the clinician considers infection and whether fluid testing is needed.
Injections around tendons require particular care because the exact tissue and technique matter. Repeated injections are not a substitute for identifying persistent disease activity or an underlying mechanical problem. Ask what benefit is expected, what limits apply and how activity should be adjusted afterward.
Systemic glucocorticoids: useful in selected circumstances
Oral or other systemic glucocorticoids can suppress inflammation rapidly, but they have substantial limitations, especially with repeated or prolonged use. They can affect glucose, blood pressure, bone health, infection risk and other systems. Rapid relief should not become the only measure of whether a long-term plan is adequate.
When a course is prescribed, clarify its purpose, duration and follow-up. Do not alter or abruptly stop an established glucocorticoid regimen without the prescriber’s instructions; the safe approach depends on the dose, duration and clinical situation.
Conventional DMARDs: a different timescale and purpose
Conventional disease-modifying antirheumatic drugs are considered for persistent inflammatory arthritis in appropriate settings. Sulfasalazine, methotrexate and sometimes leflunomide may enter the discussion, but their evidence and regulatory indications differ. They should not be described as equally proven for every form of nonpsoriatic peripheral SpA.
These medicines generally need an adequate trial over weeks to months, with the exact expectation set for the particular drug and patient. They are not taken only when a joint hurts. Monitoring helps assess safety as well as benefit.
What distinguishes the common options?
Sulfasalazine has a role in selected peripheral inflammatory arthritis. Blood-count and liver monitoring may be required, and allergy history and tolerability matter. Its use for peripheral arthritis does not establish effectiveness for dominant axial disease.
Methotrexate is commonly used in several inflammatory arthritides, including PsA. In nonpsoriatic pSpA, some decisions involve extrapolation from those settings. For inflammatory arthritis it is usually prescribed weekly, not daily; any uncertainty about the schedule must be clarified before taking it. Monitoring and reproductive planning are essential.
Leflunomide may be relevant when the clinical context supports its use, particularly in related peripheral arthritis pathways. Liver risk, blood-pressure effects, interactions and reproductive planning require discussion. Its long persistence in the body means that simply stopping tablets does not answer every safety question.
Judge benefit and burden together
Tell the team about missed doses, nausea, infections or difficulties obtaining treatment. This is information needed to interpret response, not a reason for blame. A poorly tolerated regimen may never have received an adequate trial even if several months have passed on the calendar.
Ask which manifestation the medicine targets, when it will be reviewed, which blood tests are needed and which symptoms require contact. If inflammatory disease remains active despite an appropriate trial, targeted therapy may be discussed. If swelling improves but pain persists, reassessment of the pain mechanism may be the more useful next step.
Sources and further reading
- American College of Rheumatology: NSAIDs
- NIDDK: Keeping kidneys safe—smart choices about medicines
- American College of Rheumatology: Methotrexate
- Australian Rheumatology Association: Sulfasalazine, updated February 2026
- Australian Rheumatology Association: Leflunomide, updated March 2026
- NICE NG65: Spondyloarthritis in over 16s—diagnosis and management